Silo Pharma and Kymanox Join Forces for SP-26 Ketamine Implant Device Targeting Pain Management
Shots:
- Silo Pharma has collaborated with Kymanox (SC insertaion device) to develop for SP-26 targeting fibromyalgia and chronic pain. Kymanox also serves as Silo’s regulatory partner for SPC-15, a prophylactic treatment for stress-induced disorders like PTSD
- Kymanox will lead SP-26's proof-of-concept design, prototype development, and feasibility testing to find optimal tissue insertion depth. Its preclinical study focused on SP-26 meeting FDA safety standards for potential at-home use
- Silo’s SP-26 is a ketamine-based dissolvable implant for chronic pain and fibromyalgia, designed for controlled dosage and time release
Ref: Silo Pharma | Image: Silo Pharma & Kymanox
Related News:- Silo Pharma with Sever Pharma Solutions Obtains Regulatory Approval to Conduct the Development of Ketamine Implant for Fibromyalgia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
